Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. - Perez,E.A.; Suman,V.J.; Davidson,N.E. (Cancer Res, 2009)